Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
09941 先通醫藥-B
SINOTAUPHARMA-B
Register Close2026/11/19    IPO Closing in 3 Days
Listing Date2026/11/24
COMPANY PROFILE

Beijing Sinotau International Pharmaceutical Technology Co., Ltd. is a biotechnology company, dedicated to the development and commercialization of diagnostic and therapeutic radiopharmaceuticals with considerable market potential.

--

The Group's core business model involves the development and commercialization of radiopharmaceuticals in its strategically focused areas, namely oncology, neurodegenerative diseases and cardiovascular diseases.

--

The Group had developed a staggered, indication-oriented pipeline comprising 13 assets as of 21 October 2026, five of which were self-discovered and developed and three of which were self-developed, in each case by the Group. The Group's pipeline includes two Core Products, XTR008 and XTR004, as well as two Key Products, XTR003 and XTR006.

--

The Group's customers primarily comprise healthcare institutions and distributors that directly purchase pharmaceutical products and radionuclides from the Group, as well as pharmaceutical enterprises that purchase CRO or CDMO services from the Group. For Core Products, the Group held 25 registered patents, 23 of which are registered in China and two are registered in Japan, and 18 patent applications.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot50
GLOBAL OFFERING
No. of Offer Shares6.56M H shares
No. of International Offer Shares5.90M H shares
No. of HK Offer Shares0.66M H shares
Offer Price$52.0 - $68.0
Stock Code9941
Sponsor(s)GF Capital (Hong Kong) Limited, China International Capital Corporation Hong Kong Securities Limited, CITIC Securities (Hong Kong) Limited
Underwriter(s)GF Securities (Hong Kong) Brokerage Limited, China International Capital Corporation Hong Kong Securities Limited, CLSA Limited, CMB International Capital Limited, DBS Asia Capital Limited, China Galaxy International Securities (Hong Kong) Co., Limited, BOCI Asia Limited, ABCI Securities Company Limited, Guolian Securities International Capital Co., Limited, BOCOM International Securities Limited, CMBC Securities Company Limited, Zheshang International Financial Holdings Co., Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited
TIME TABLE
Application PeriodNov 16 (Mon) - noon, Nov 19 (Thu)
Price Determination DateNov 20 (Fri)
Result Announcement DateNot later than Nov 23 (Mon)
Result Announcement DateOn or before Nov 24 (Tue)
Result Announcement DateOn or before Nov 24 (Tue)
Dealings in Shares commence onNov 24, 2026. (Tue)
Reallocation of Shares Offered
Sales Statistics (HKD)
Offer Price$52.0 - $68.0
Capitalization3.41B - 4.46B
NAV / share ($)$23.13 - $24.66 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 60, the net proceeds raised would be HKD 329.10M, of which
88% : Research, development and registrational filings of Core Product
4.9% : Research and development of other product candidates
1.1% : Reinforcement of sales and marketing capabilities
1.1% : Construction of a new manufacturing facility in Tianjin
5% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
:
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2026 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.